François Goldwasser

François Goldwasser

Auto-generated profile, based on publicly available information

François Goldwasser

Medical Oncology Department, ARIANE Program, Institut du Cancer Paris CARPEM, Hôpital Cochin, Paris, France

Research Focus & Metrics

Academic Career Length

20Years (2007-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 November 2017 in Bulletin du Cancer
Verified
Journal Article
Closed access
BRBruno Raynard
Bruno Raynard
XHXavier Hébuterne
Xavier Hébuterne
FGFrançois Goldwasser
François Goldwasser
AHAli Ait Hssain
Ali Ait Hssain
PLPascale Dubray Longeras
Pascale Dubray Longeras
EGEmmanuel Gyan
Emmanuel Gyan

20 June 2007 in Journal of Clinical Oncology
Verified
Journal Article
Closed access
CMC. Mateus
C. Mateus
WCW. Cacheux
W. Cacheux
ELE. Lemarié
E. Lemarié
MMMorgan Michalet
Morgan Michalet
CMC. Beauvillain de Montreuil
C. Beauvillain de Montreuil
FGFrench Nutrition Oncology Study Group
French Nutrition Oncology Study Group
9126 Background: The evaluation of the performance status (PS) is universally used in oncology and a PS of 2 is known as associated with reduced survival and increased risk of toxicity following chemotherapy. The aim of the present study was to evaluate the prevalence of malnutrition in a non selected population of cancer patients (pts) and how malnutrition correlates with poor PS. Methods: A prospective one-day prevalence survey was carried out in 154 wards of private or public hospitals in 24 cities in France. Height, present and usual body weight were assessed in outpatients and inpatients who were present that day. Malnutrition was defined as a Body Mass Index <18.5 or 10% from the beginning of the disease. The prevalence of malnutrition was studied in the overall population and stratified for the type of cancer and the PS. Results: 2,068 pts (1,189 men and 879 women) aged 60±13 yrs were evaluated and nutritional status was available in 1,903 pts. The PS was 0 or 1 in 52.3% of pts, 2 in 25.3%, 3 or 4 in 22.4%. Overall, 38% of pts were malnourished. Prevalence of malnutrition according to the primary tumor was: pancreas (n=42): 67%, oesophagus (n=41): 61%, stomach (n=41): 59%, head and neck (n=366): 49%, lung (n=247): 45%, ovary/uterus (n=87): 45%, colon/rectum (n=191): 39%, leukemia/lymphoma (n=377): 34%, breast (n=229): 21%, prostate (n=72): 14%. The prevalence of malnutrition was 14.4%, 31.4%, 52.3%, 53.6%, and 65.3% in pts with a PS ranging from 0 to 4, respectively. In comparison to PS-0 pts, Relative risk (RR) of malnutrition was 2.5 (p < 0.0001) in PS-1 pts and 6.4 in PS-2 pts (p50% of PS-2 pts. Systematic screening and care of malnutrition is mandatory to improve the PS and subsequently treatment tolerability in these pts. No significant financial relationships to disclose.

1 August 2007 in Journal of Thoracic Oncology
Verified
Journal Article
Open access
PDF file
ELEtienne Lemarie
Etienne Lemarie
FGFrancois Goldwasser
Francois Goldwasser
MMMauricette Michallet
Mauricette Michallet
CMClaude Beauvillain De Montreuil
Claude Beauvillain De Montreuil
XHXavier Hebuterne
Xavier Hebuterne
In 1980, Dewys WD et al. (Am J Med 1980;69:491-7) have demonstrated a high prevalence of malnutrition in cancer patients, including lung cancer. The aim of the present study was to re-evaluate, 25 years later, the prevalence of malnutrition in a non selected population of cancer patients and also the nutritional support to these patients.

1 March 2017 in The American Journal of Clinical Nutrition
Verified
Journal Article
Closed access
CVClara Vazeille
Clara Vazeille
AJAnne Jouinot
Anne Jouinot
JDJean-Philippe Durand
Jean-Philippe Durand
LCLuc Cynober
Luc Cynober
FGFrançois Goldwasser
François Goldwasser

15 October 2025 in Supportive Care in Cancer
Verified
Journal Article
Open access
PDF file
GPGermain Perrin
Germain Perrin
ATAudrey Thomas-Schoemann
Audrey Thomas-Schoemann
FGFrançois Goldwasser
François Goldwasser
PBPascaline BOUDOU-ROUQUETTE
Pascaline BOUDOU-ROUQUETTE
NDNicolas Delanoy
Nicolas Delanoy
VKVirginie Korb-Savoldelli
Virginie Korb-Savoldelli
Purpose Optimal medication adherence to oral systemic anticancer therapies (SACTs) is critical for effective cancer management. However, the factors influencing adherence, particularly in relation to the longitudinal course of the disease, remain poorly understood. This study aimed to identify factors associated with medication adherence trajectories among patients initiating oral SACTs. Methods A multicentre cohort study was conducted among patients initiating oral SACTs and enrolled in a multidisciplinary risk management programme during day hospitalisation. Medication adherence trajectories were identified using group-based trajectory modelling (GBTM), based on scores from a validated six-item medication adherence questionnaire. Factors associated with trajectory allocation were examined using bias-reduced multinomial logistic regression. Results A total of 135 participants were included, of whom 71 provided at least two adherence scores for trajectory modelling. Three latent groups of adherence trajectories were identified: (i) continuous optimal adherence (73.2%), (ii) improving adherence (9.9%), and (iii) declining adherence (16.9%). In multivariate analysis, subjects belonging to the declining adherence group were more likely to belong to the low-income category. Conclusion GBTM identified three distinct and clinically relevant patterns of oral SACT adherence trajectories among outpatients followed during day hospitalisation. Understanding the factors influencing these trajectories provides a dynamic perspective on the complex phenomenon of medication adherence and highlights actionable factors to support tailored health interventions.